Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The prolongation of the EPAAC trial - NCT00152464 (the Early Prevention of Asthma in Atopic Children). A multi-country, double blind, placebo (PLC) controlled, follow-up trial with 3 parallel groups (LCTZ-LCTZ, LCTZ-PLC and PLC-PLC) : evaluation of the long term efficacy and safety of levocetirizine (LCTZ) (5 mg/mL oral drops -0.125 mg/kg b.w. b.i.d. [twice daily]) administered for an additional 18 months period in preventing the onset of asthma in children coming from the EPAAC trial.

Trial Profile

The prolongation of the EPAAC trial - NCT00152464 (the Early Prevention of Asthma in Atopic Children). A multi-country, double blind, placebo (PLC) controlled, follow-up trial with 3 parallel groups (LCTZ-LCTZ, LCTZ-PLC and PLC-PLC) : evaluation of the long term efficacy and safety of levocetirizine (LCTZ) (5 mg/mL oral drops -0.125 mg/kg b.w. b.i.d. [twice daily]) administered for an additional 18 months period in preventing the onset of asthma in children coming from the EPAAC trial.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levocetirizine (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 20 Oct 2009 Additional locations identified as reported by ClinicalTrials.gov.
    • 13 Mar 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov, last updated 13-Mar-2009.
    • 13 Mar 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top